id
stringlengths
9
11
source
stringclasses
1 value
title
stringlengths
15
560
text
stringlengths
2k
153k
PMC10747562
core_pubmed_pmc
Pharmacokinetic Study of Islatravir and Etonogestrel Implants in Macaques
Pharmacokinetic Study of Islatravir and Etonogestrel Implants in Macaques Abstract Abstract The prevention of HIV and unintended pregnancies is a public health priority. Multi-purpose prevention technologies capable of long-acting HIV and pregnancy prevention are desirable for women. Here, we utilized a preclinical mac...
PMC4047294
core_pubmed_pmc
Safety and Pharmacokinetics of Intravenous Zanamivir Treatment in Hospitalized Adults With Influenza: An Open-label, Multicenter, Single-Arm, Phase II Study
Safety and Pharmacokinetics of Intravenous Zanamivir Treatment in Hospitalized Adults With Influenza: An Open-label, Multicenter, Single-Arm, Phase II Study Abstract Abstract Background. Intravenous zanamivir is a neuraminidase inhibitor suitable for treatment of hospitalized patients with severe influenza. Methods. Pa...
PMC7984322
core_pubmed_pmc
The Bioequivalence of Two Peficitinib Formulations, and the Effect of Food on the Pharmacokinetics of Peficitinib: Two‐Way Crossover Studies of a Single Dose of 150 mg Peficitinib in Healthy Volunteers
The Bioequivalence of Two Peficitinib Formulations, and the Effect of Food on the Pharmacokinetics of Peficitinib: Two‐Way Crossover Studies of a Single Dose of 150 mg Peficitinib in Healthy Volunteers Abstract Abstract The marketed tablet formulation of peficitinib differs from the tablet used during the clinical tria...
PMC4982581
core_pubmed_pmc
Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB 1 polymorphism
Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB 1 polymorphism Abstract Crizotinib is a standard treatment for advanced ALK ‐positive non‐small‐cell lung cancer ( NSCLC ). We undertook this study to investigate the pharmacokinetics of crizotinib and clinical and pha...
PMC6384574
core_pubmed_pmc
Colistin Use in Patients with Chronic Kidney Disease: Are We Underdosing Patients?
Colistin Use in Patients with Chronic Kidney Disease: Are We Underdosing Patients? Abstract Abstract Colistin is administered as its inactive prodrug colistimethate (CMS). Selection of an individualized CMS dose for each patient is difficult due to its narrow therapeutic window, especially in patients with chronic kidn...
PMC3603432
core_pubmed_pmc
From Pediatric Covariate Model to Semiphysiological Function for Maturation: Part II—Sensitivity to Physiological and Physicochemical Properties
From Pediatric Covariate Model to Semiphysiological Function for Maturation: Part II—Sensitivity to Physiological and Physicochemical Properties Abstract Abstract To develop a maturation function for drug glucuronidation in children, that can be used in population and physiologically based modeling approaches, the phys...
PMC10450003
core_pubmed_pmc
Pharmacokinetics, Metabolism, and Excretion of Intravenous [14C]Difelikefalin in Healthy Subjects and Subjects on Hemodialysis
Pharmacokinetics, Metabolism, and Excretion of Intravenous [14C]Difelikefalin in Healthy Subjects and Subjects on Hemodialysis Abstract Background and Objective Difelikefalin, a selective kappa-opioid receptor agonist, is the first approved treatment for moderate-to-severe pruritus in patients with end-stage renal dise...
PMC9292349
core_pubmed_pmc
Population Pharmacokinetic Model Development and Simulation for Recombinant Erwinia Asparaginase Produced in Pseudomonas fluorescens (JZP‐458)
Population Pharmacokinetic Model Development and Simulation for Recombinant Erwinia Asparaginase Produced in Pseudomonas fluorescens (JZP‐458) Abstract Abstract JZP‐458 is a recombinant Erwinia asparaginase produced using a novel Pseudomonas fluorescens expression platform that yields an enzyme expected to lack immunol...
PMC6812644
core_pubmed_pmc
Pharmacokinetics of Tylvalosin in Broiler Turkeys ( Meleagris Gallopavo ) After Single Intravenous and Oral Administration
Pharmacokinetics of Tylvalosin in Broiler Turkeys ( Meleagris Gallopavo ) After Single Intravenous and Oral Administration Abstract Pharmacokinetics of tylvalosin (TVN) were determined in eight broiler turkeys following a single intravenous (IV) and peroral (PO) administration of 25 mg/kg b.w using a crossover design w...
PMC9387316
core_pubmed_pmc
Bilosomes as a promising nanoplatform for oral delivery of an alkaloid nutraceutical: improved pharmacokinetic profile and snowballed hypoglycemic effect in diabetic rats
Bilosomes as a promising nanoplatform for oral delivery of an alkaloid nutraceutical: improved pharmacokinetic profile and snowballed hypoglycemic effect in diabetic rats Abstract Abstract Diabetes mellitus is a life-threatening metabolic disease. At the moment, there is no effective treatment available to combat it. I...
PMC11305320
core_pubmed_pmc
A novel highly sensitive inner filter effect-based fluorescence immunoassay with quantum dots for bioanalysis of zolbetuximab, a monoclonal antibody used for immunotherapy of gastric and gastroesophageal junction adenocarcinoma
A novel highly sensitive inner filter effect-based fluorescence immunoassay with quantum dots for bioanalysis of zolbetuximab, a monoclonal antibody used for immunotherapy of gastric and gastroesophageal junction adenocarcinoma Abstract Abstract Zolbetuximab (ZOL) is a groundbreaking monoclonal antibody targeting CLDN ...
PMC9496116
core_pubmed_pmc
Oroxylin A: A Promising Flavonoid for Prevention and Treatment of Chronic Diseases
Oroxylin A: A Promising Flavonoid for Prevention and Treatment of Chronic Diseases Abstract Abstract There have been magnificent advancements in the understanding of molecular mechanisms of chronic diseases over the past several years, but these diseases continue to be a considerable cause of death worldwide. Most of t...
PMC7221793
core_pubmed_pmc
Metabolism and Pharmacokinetics of SP-8356, a Novel (1 S )-(−)-Verbenone Derivative, in Rats and Dogs and Its Implications in Humans
Metabolism and Pharmacokinetics of SP-8356, a Novel (1 S )-(−)-Verbenone Derivative, in Rats and Dogs and Its Implications in Humans Abstract Abstract (1 S ,5 R )-4-(( E )-3,4-dihydroxy-5-methoxystryryl)-6,6-dimethylbicylco[3.1.1]hept-3-en-2-one (SP-8356) is a novel (1 S )-(−)-verbenone derivative that is currently in ...
PMC8230846
core_pubmed_pmc
Subcutaneously Injectable Hyaluronic Acid Hydrogel for Sustained Release of Donepezil with Reduced Initial Burst Release: Effect of Hybridization of Microstructured Lipid Carriers and Albumin
Subcutaneously Injectable Hyaluronic Acid Hydrogel for Sustained Release of Donepezil with Reduced Initial Burst Release: Effect of Hybridization of Microstructured Lipid Carriers and Albumin Abstract Abstract The daily oral administration of acetylcholinesterase (AChE) inhibitors for Alzheimer’s disease features low p...
PMC12859392
core_pubmed_pmc
Model Informed Precision Dosing of Tacrolimus in Children Following Heart Transplant
Model Informed Precision Dosing of Tacrolimus in Children Following Heart Transplant Abstract Abstract Tacrolimus is a first‐line immunosuppressant used after solid organ transplantation that suffers from extensive intra‐ and inter‐patient variability and a narrow therapeutic window. Its critical role in a fragile popu...
PMC9197538
core_pubmed_pmc
Population pharmacokinetics of mobocertinib in healthy volunteers and patients with non–small cell lung cancer
Population pharmacokinetics of mobocertinib in healthy volunteers and patients with non–small cell lung cancer Abstract Abstract Mobocertinib is an oral tyrosine kinase inhibitor approved for treatment of patients with locally advanced or metastatic non‐small cell lung cancer (mNSCLC) with epidermal growth factor recep...
PMC8370236
core_pubmed_pmc
Population Pharmacokinetics of Meropenem and Vaborbactam Based on Data from Noninfected Subjects and Infected Patients
Population Pharmacokinetics of Meropenem and Vaborbactam Based on Data from Noninfected Subjects and Infected Patients Abstract ABSTRACT Meropenem-vaborbactam is a broad-spectrum carbapenem–beta-lactamase inhibitor combination approved in the United States and Europe to treat patients with complicated urinary tract inf...
PMC11103544
core_pubmed_pmc
Revealing the potential bioactive components and mechanism of Qianhua Gout Capsules in the treatment of gouty arthritis through network pharmacology, molecular docking and pharmacodynamic study strategies
Revealing the potential bioactive components and mechanism of Qianhua Gout Capsules in the treatment of gouty arthritis through network pharmacology, molecular docking and pharmacodynamic study strategies Abstract Recent clinical studies have confirmed the effectiveness of Qianhua Gout Capsules (QGC) in the treatment o...
PMC12408700
core_pubmed_pmc
The establishment of an expected concentration reference range for eltrombopag in the individualized treatment of pediatric immune thrombocytopenia
The establishment of an expected concentration reference range for eltrombopag in the individualized treatment of pediatric immune thrombocytopenia Abstract Abstract Background Differences in the clinical efficacy and adverse drug reactions (ADRs) of eltrombopag (ELT) in children with immune thrombocytopenia (ITP) may ...
PMC7540423
core_pubmed_pmc
Predictors of Systemic Exposure to Topical Crisaborole: A Nonlinear Regression Analysis
Predictors of Systemic Exposure to Topical Crisaborole: A Nonlinear Regression Analysis Abstract Abstract Crisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild to moderate atopic dermatitis. Results from 2 randomized, double‐blind, vehicle‐controlled phase 3 studies showed ...
PMC8299485
core_pubmed_pmc
Prediction of Minocycline Activity in the Gut From a Pig Preclinical Model Using a Pharmacokinetic -Pharmacodynamic Approach
Prediction of Minocycline Activity in the Gut From a Pig Preclinical Model Using a Pharmacokinetic -Pharmacodynamic Approach Abstract Abstract The increase of multidrug-resistant (MDR) bacteria has renewed interest in old antibiotics, such as minocycline, that can be active against various MDR Gram-negative pathogens. ...
PMC7098142
core_pubmed_pmc
Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis
Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis Abstract Background ABP 710 is being developed as a biosimilar to infliximab reference product (RP). Analytical similarity and pharmacokinetic equivalence between the two h...
PMC10818312
core_pubmed_pmc
Ocular and Plasma Pharmacokinetics of Enavogliflozin Ophthalmic Solution in Preclinical Species
Ocular and Plasma Pharmacokinetics of Enavogliflozin Ophthalmic Solution in Preclinical Species Abstract Abstract An enavogliflozin ophthalmic solution (DWRX2008) is being developed to treat diabetic retinopathy and macular edema. This study evaluated the ocular distribution and plasma pharmacokinetics (PKs) of enavogl...
PMC12041775
core_pubmed_pmc
Repurposing major metabolites of lamiaceae family as potential inhibitors of α -synuclein aggregation to alleviate neurodegenerative diseases: an in silico approach
Repurposing major metabolites of lamiaceae family as potential inhibitors of α -synuclein aggregation to alleviate neurodegenerative diseases: an in silico approach Abstract Abstract Neurodegenerative disorders (NDs) are typically characterized by progressive loss of neuronal function and the deposition of misfolded pr...
PMC8545752
core_pubmed_pmc
Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review
Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review Abstract Abstract Background Patients affected by poverty-related infectious diseases (PRDs) are disproportionally affected by malnutrition. To optimize treatment of patients affected by PRD...
PMC4476083
core_pubmed_pmc
The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis
The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis Abstract Abstract Introduction The pleiotropic cytokine interleukin-6 (IL-6) plays an important role in the pathogenesis of different diseases, including rheumatoid arthritis (RA). A...
PMC4145871
core_pubmed_pmc
Pharmacokinetics and safety of single doses of drisapersen in non-ambulant subjects with Duchenne muscular dystrophy: Results of a double-blind randomized clinical trial
Pharmacokinetics and safety of single doses of drisapersen in non-ambulant subjects with Duchenne muscular dystrophy: Results of a double-blind randomized clinical trial Abstract Duchenne muscular dystrophy (DMD) is a progressive, lethal neuromuscular disorder caused by the absence of dystrophin protein due to mutation...
PMC8157232
core_pubmed_pmc
Colistin Dosing Regimens against Pseudomonas aeruginosa in Critically Ill Patients: An Application of Monte Carlo Simulation
Colistin Dosing Regimens against Pseudomonas aeruginosa in Critically Ill Patients: An Application of Monte Carlo Simulation Abstract Our aims are to assess various colistin dosing regimens against Pseudomonas aeruginosa ( P. aeruginosa ) infection in critically ill patients and to propose an appropriate regimen based ...
PMC6944649
core_pubmed_pmc
Population Pharmacokinetics, Efficacy Exposure-response Analysis, and Model-based Meta-analysis of Fenebrutinib in Subjects with Rheumatoid Arthritis
Population Pharmacokinetics, Efficacy Exposure-response Analysis, and Model-based Meta-analysis of Fenebrutinib in Subjects with Rheumatoid Arthritis Abstract Abstract Purpose Fenebrutinib (GDC-0853), a Bruton’s tyrosine kinase (BTK) inhibitor was investigated in a Phase 2 clinical trial in patients with rheumatoid art...
PMC12944407
core_pubmed_pmc
A Digital Twin of the Angiotensin II Receptor Blocker Losartan: Physiologically Based Modeling of Blood Pressure Regulation
A Digital Twin of the Angiotensin II Receptor Blocker Losartan: Physiologically Based Modeling of Blood Pressure Regulation Abstract Background/Objectives: Losartan, an angiotensin II receptor blocker (ARB) used to treat hypertension and heart failure, shows significant variability in pharmacokinetics (PK) and pharmaco...
PMC10268535
core_pubmed_pmc
Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementia
Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementia Abstract Background Heterozygous loss-of-function mutations in the progranulin (PGRN) gene ( GRN ) cause a reduction in PGRN and lead to the development of frontotemporal dementia (FTD- GRN ). PGRN is a secreted lysosomal chaperone, immune r...
PMC6974966
core_pubmed_pmc
Abnormal cisatracurium pharmacodynamics and pharmacokinetics among patients with severe aortic regurgitation during anesthetic induction
Abnormal cisatracurium pharmacodynamics and pharmacokinetics among patients with severe aortic regurgitation during anesthetic induction Abstract Background This study was designed to examine whether severe aortic regurgitation will affect the pharmacodynamics (PD) and pharmacokinetics (PK) of cisatracurium during anes...
PMC9818435
core_pubmed_pmc
Palmitoyl Carnitine-Anchored Nanoliposomes for Neovasculature-Specific Delivery of Gemcitabine Elaidate to Treat Pancreatic Cancer
Palmitoyl Carnitine-Anchored Nanoliposomes for Neovasculature-Specific Delivery of Gemcitabine Elaidate to Treat Pancreatic Cancer Abstract Simple Summary Despite the availability of numerous therapeutic approaches, pancreatic ductal adenocarcinoma still stands as one of the most fatal cancers worldwide. Nanoliposomes ...
PMC12939389
core_pubmed_pmc
Intracellular Pharmacokinetics of Antidiabetic Drugs: A Focused Narrative Review of Subcellular Distribution (2015–2025)
Intracellular Pharmacokinetics of Antidiabetic Drugs: A Focused Narrative Review of Subcellular Distribution (2015–2025) Abstract Abstract Background/Objectives: The efficacy of antidiabetic drugs is determined by intracellular target exposure rather than solely by plasma concentrations. This review synthesizes current...
PMC11722186
core_pubmed_pmc
Applications of Au 25 Nanoclusters in Photon-Based Cancer Therapies
Applications of Au 25 Nanoclusters in Photon-Based Cancer Therapies Abstract Abstract Atomically precise gold nanoclusters (AuNCs) exhibit unique physical and optical properties, making them highly promising for targeted cancer therapy. Their small size enhances cellular uptake, facilitates rapid distribution to tumor ...
PMC9643549
core_pubmed_pmc
In silico analysis of noscapine compounds as anti-tumor agents targeting the tubulin receptor
In silico analysis of noscapine compounds as anti-tumor agents targeting the tubulin receptor Abstract Abstract Objective This research aims to develop a mathematical model that relates the structural features of noscapine with anti-tumor activity, to explains the mode of binding between noscapine compounds and the tar...
PMC9252316
core_pubmed_pmc
The Impact of Pharmacogenetics on Pharmacokinetics and Pharmacodynamics in Neonates and Infants: A Systematic Review
The Impact of Pharmacogenetics on Pharmacokinetics and Pharmacodynamics in Neonates and Infants: A Systematic Review Abstract Abstract In neonates, pharmacogenetics has an additional layer of complexity. This is because in addition to genetic variability in genes that code for proteins relevant to clinical pharmacology...
PMC9942444
core_pubmed_pmc
The Evolution Toward Designer Benzodiazepines in Drug-Facilitated Sexual Assault Cases
The Evolution Toward Designer Benzodiazepines in Drug-Facilitated Sexual Assault Cases Abstract Abstract Drug-facilitated sexual assault (DFSA) is a crime where the victim is unable to provide sexual consent due to incapacitation resulting from alcohol or drug consumption. Due to the large number of substances possibly...
PMC8592506
core_pubmed_pmc
Development of physiologically‐based pharmacokinetic models for standard of care and newer tuberculosis drugs
Development of physiologically‐based pharmacokinetic models for standard of care and newer tuberculosis drugs Abstract Abstract Tuberculosis (TB) remains a global health problem and there is an ongoing effort to develop more effective therapies and new combination regimes that can reduce duration of treatment. The purp...
PMC8929358
core_pubmed_pmc
Metabolism and disposition of opicapone in the rat and metabolic enzymes phenotyping
Metabolism and disposition of opicapone in the rat and metabolic enzymes phenotyping Abstract Abstract Opicapone (2,5‐dichloro‐3‐(5‐(3,4‐dihydroxy‐5‐nitrophenyl)‐1,2,4‐oxadiazol‐3‐yl)‐4,6‐dimethylpyridine 1‐oxide) is a selective catechol‐O‐methyltransferase inhibitor that has been granted marketing authorization in Eur...
PMC7306622
core_pubmed_pmc
A Novel Physiologically Based Model of Creatinine Renal Disposition to Integrate Current Knowledge of Systems Parameters and Clinical Observations
A Novel Physiologically Based Model of Creatinine Renal Disposition to Integrate Current Knowledge of Systems Parameters and Clinical Observations Abstract Abstract Creatinine is the most common clinical biomarker of renal function. As a substrate for renal transporters, its secretion is susceptible to inhibition by dr...
PMC7292807
core_pubmed_pmc
A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment
A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment Abstract Abstract Introduction As patients who receive cannabidiol (CBD) may have co-existing renal morbidities, it is important to understand whethe...
PMC11761852
core_pubmed_pmc
Development and Evaluation of Aloperine-Loaded Nanostructured Lipid Carriers for the Treatment of Pulmonary Arterial Hypertension
Development and Evaluation of Aloperine-Loaded Nanostructured Lipid Carriers for the Treatment of Pulmonary Arterial Hypertension Abstract Abstract Objective This study focuses on the development and evaluation of nanostructured lipid carriers (NLCs) loaded with aloperine as a potential therapeutic approach for the tre...
PMC4020582
core_pubmed_pmc
Open-label Bendamustine Monotherapy for Pediatric Patients With Relapsed or Refractory Acute Leukemia: Efficacy and Tolerability
Open-label Bendamustine Monotherapy for Pediatric Patients With Relapsed or Refractory Acute Leukemia: Efficacy and Tolerability Abstract Supplemental Digital Content is available in the text. This open-label, single-arm, phase I/II, dose-escalation study was designed to determine the recommended phase II dose (RP2D), ...
PMC9133860
core_pubmed_pmc
Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels but not with clinical worsening
Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels but not with clinical worsening Abstract Background: Higher infliximab trough levels (TLs) correlate with better clinical, inflammatory, and endoscopic outcomes among inflammatory bowel disease (IBD) patients...
PMC12516641
core_pubmed_pmc
Testosterone Pellets in Women: Revisiting Safety and Clinical Outcomes
Testosterone Pellets in Women: Revisiting Safety and Clinical Outcomes Abstract Abstract Testosterone is the most abundant biologically active gonadal steroid in women, yet its therapeutic role remains controversial. Current guidelines restrict its use to hypoactive sexual desire disorder (HSDD) with transdermal formul...
PMC8397472
core_pubmed_pmc
In Silico Pharmacokinetics, ADMET Study and Conceptual DFT Analysis of Two Plant Cyclopeptides Isolated From Rosaceae as a Computational Peptidology Approach
In Silico Pharmacokinetics, ADMET Study and Conceptual DFT Analysis of Two Plant Cyclopeptides Isolated From Rosaceae as a Computational Peptidology Approach Abstract Abstract This research presents the outcomes of a computational determination of the chemical reactivity and bioactivity properties of two plant cyclopep...
PMC5575535
core_pubmed_pmc
Phase I randomized study of KHK 4083, an anti‐ OX 40 monoclonal antibody, in patients with mild to moderate plaque psoriasis
Phase I randomized study of KHK 4083, an anti‐ OX 40 monoclonal antibody, in patients with mild to moderate plaque psoriasis Abstract Abstract Background OX 40 ( CD 134) is expressed in lesional but not healthy skin of patients with psoriasis. KHK 4083 is a fully human monoclonal antibody against OX 40. Objective The p...
PMC12203663
core_pubmed_pmc
Evaluation of ceftazidime/avibactam in combination with colistin against KPC-2-producing Klebsiella pneumoniae in static and dynamic time-kill experiments
Evaluation of ceftazidime/avibactam in combination with colistin against KPC-2-producing Klebsiella pneumoniae in static and dynamic time-kill experiments Abstract Abstract Objectives Ceftazidime/avibactam is used for severe infections caused by carbapenemase-producing Klebsiella pneumoniae . Combination therapy with o...
PMC6781499
core_pubmed_pmc
Pharmacokinetic Study of NADPH Oxidase Inhibitor Ewha-18278, a Pyrazole Derivative
Pharmacokinetic Study of NADPH Oxidase Inhibitor Ewha-18278, a Pyrazole Derivative Abstract In a previous study, the specific NOX1/2/4 inhibitor Ewha-18278 was confirmed as a possible treatment for osteoporosis both in vitro and in vivo. Here, we investigated the pharmacokinetics (PK) of the compound by intravenous (IV...
PMC11247119
core_pubmed_pmc
SAAM II : A general mathematical modeling rapid prototyping environment
SAAM II : A general mathematical modeling rapid prototyping environment Abstract Abstract Simulation Analysis and Modeling II (SAAM II) is a graphical modeling software used in life sciences for compartmental model analysis, particularly, but not exclusively, appreciated in pharmacokinetics (PK) and pharmacodynamics (P...
PMC8070696
core_pubmed_pmc
Pharmacokinetics and Safety of a Novel Oral Liquid Formulation of 13- cis Retinoic Acid in Children with Neuroblastoma: A Randomized Crossover Clinical Trial
Pharmacokinetics and Safety of a Novel Oral Liquid Formulation of 13- cis Retinoic Acid in Children with Neuroblastoma: A Randomized Crossover Clinical Trial Abstract Abstract Simple Summary The availability of a child-friendly drug formulation can be an important determinant of therapeutic success. 13- cis -retinoic a...
PMC5695804
core_pubmed_pmc
Reduced order modeling and analysis of the human complement system
Reduced order modeling and analysis of the human complement system Abstract Complement is an important pathway in innate immunity, inflammation, and many disease processes. However, despite its importance, there are few validated mathematical models of complement activation. In this study, we developed an ensemble of e...
PMC11357421
core_pubmed_pmc
Nanoparticle-Based Drug Delivery Systems in Inhaled Therapy: Improving Respiratory Medicine
Nanoparticle-Based Drug Delivery Systems in Inhaled Therapy: Improving Respiratory Medicine Abstract Inhaled nanoparticle (NP) therapy poses intricate challenges in clinical and pharmacodynamic realms. Recent strides have revolutionized NP technology by enabling the incorporation of diverse molecules, thus circumventin...
PMC12379728
core_pubmed_pmc
Limited 12-hour pharmacokinetic assessment of CBD and CBDA isolates compared to their full-spectrum extracts in healthy adult beagles
Limited 12-hour pharmacokinetic assessment of CBD and CBDA isolates compared to their full-spectrum extracts in healthy adult beagles Abstract Abstract Introduction The rapidly expanding market for therapeutic cannabinoid products has intensified research on their safety and efficacy in pets. Full-spectrum hemp extract...
PMC11612359
core_pubmed_pmc
Handling delayed or missed direct oral anticoagulant doses: model-informed individual remedial dosing
Handling delayed or missed direct oral anticoagulant doses: model-informed individual remedial dosing Abstract Key Points • The proposed model-informed remedial approach is superior to existing guidelines, minimizing the time spent outside the therapeutic window. • A web-based dashboard has been devised to offer remedi...
PMC7479000
core_pubmed_pmc
Cisplatin and carboplatin pharmacokinetics in a pediatric patient with hepatoblastoma receiving peritoneal dialysis
Cisplatin and carboplatin pharmacokinetics in a pediatric patient with hepatoblastoma receiving peritoneal dialysis Abstract Purpose Cisplatin and carboplatin are frequently used drugs in the treatment of pediatric hepatoblastoma. Dosing guidelines for these drugs in children requiring peritoneal dialysis are lacking. ...
PMC10204490
core_pubmed_pmc
Incubation Time Influences Organic Anion Transporter 1 Kinetics and Renal Clearance Predictions
Incubation Time Influences Organic Anion Transporter 1 Kinetics and Renal Clearance Predictions Abstract Accurate predictions of drug uptake transporter involvement in renal excretion of xenobiotics require determination of in vitro transport kinetic parameters under initial-rate conditions. The purpose of the present ...
PMC12050655
core_pubmed_pmc
Tangeretin Improves the Memory of Swiss Mice, Suggesting Potential Molecular Interventions Through Animal Behavior Assessments and In Silico Studies
Tangeretin Improves the Memory of Swiss Mice, Suggesting Potential Molecular Interventions Through Animal Behavior Assessments and In Silico Studies Abstract ABSTRACT Introduction Tangeretin (TAN), a polymethoxylated flavone from citrus peels, exhibits neuroprotective, anti‐inflammatory, and antioxidant properties. Thi...
PMC12450600
core_pubmed_pmc
The role of cangrelor in acute and high-risk PCI settings
The role of cangrelor in acute and high-risk PCI settings Abstract Abstract Dual antiplatelet therapy with acetylsalicylic acid (ASA) and an oral P2Y 12 inhibitor is the standard of care to prevent thrombotic complications in patients with acute coronary syndromes undergoing percutaneous coronary intervention (PCI). Ho...
PMC10326142
core_pubmed_pmc
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation Abstract Abstract Purpose Aberrant alterations of ERBB receptor tyrosine kinases lead to tumorig...
PMC8994846
core_pubmed_pmc
Hyperinflammation Reduces Midazolam Metabolism in Critically Ill Adults with COVID-19
Hyperinflammation Reduces Midazolam Metabolism in Critically Ill Adults with COVID-19 Abstract Background and Objective Many patients treated for COVID-19 related acute respiratory distress syndrome in the intensive care unit are sedated with the benzodiazepine midazolam. Midazolam undergoes extensive metabolism by CYP...
PMC10439801
core_pubmed_pmc
Comparative Pharmacokinetics and Bioequivalence Evaluation of Two Formulations of Pramipexole Dihydrochloride Extended-Release Tablets in Healthy Chinese Subjects Under Fasted and Fed States: A Randomized, Open-Label, Single-Dose, Two-Period Crossover Clinical Trial
Comparative Pharmacokinetics and Bioequivalence Evaluation of Two Formulations of Pramipexole Dihydrochloride Extended-Release Tablets in Healthy Chinese Subjects Under Fasted and Fed States: A Randomized, Open-Label, Single-Dose, Two-Period Crossover Clinical Trial Abstract Abstract Background Pramipexole dihydrochlor...
PMC7870502
core_pubmed_pmc
Unraveling the Contribution of Fluid Therapy to the Development of Augmented Renal Clearance in a Piglet Model
Unraveling the Contribution of Fluid Therapy to the Development of Augmented Renal Clearance in a Piglet Model Abstract Abstract Augmented renal clearance (ARC) observed in the critically ill pediatric population has received an increased attention over the last years due to its major impact on the disposition and phar...
PMC9290022
core_pubmed_pmc
Meta‐analysis of Pharmacokinetic/Pharmacodynamic Results of 3 Phase 1 Studies with Biosimilar Pegfilgrastim
Meta‐analysis of Pharmacokinetic/Pharmacodynamic Results of 3 Phase 1 Studies with Biosimilar Pegfilgrastim Abstract Abstract A meta‐analysis using data from 3 phase 1 studies evaluated the pharmacokinetics (PK) and pharmacodynamics (PD) of Sandoz biosimilar versus US‐ and EU‐reference pegfilgrastim. The studies includ...
PMC10746415
core_pubmed_pmc
Pharmacokinetics and bioequivalence of Withania somnifera (Ashwagandha) extracts – A double blind, crossover study in healthy adults
Pharmacokinetics and bioequivalence of Withania somnifera (Ashwagandha) extracts – A double blind, crossover study in healthy adults Abstract Introduction Withania somnifera (WS) or ashwagandha is an adaptogenic plant used extensively in traditional medicines and as a food supplement. Despite a long history of use and ...
PMC7848235
core_pubmed_pmc
Experimental and In Silico Analysis of Cordycepin and its Derivatives as Endometrial Cancer Treatment
Experimental and In Silico Analysis of Cordycepin and its Derivatives as Endometrial Cancer Treatment Abstract The aim of this study was to investigate the inhibition effects of cordycepin and its derivatives on endometrial cancer cell growth. Cytotoxicity MTT assays, clonogenic assays, and flow cytometry were used to ...
PMC12263802
core_pubmed_pmc
A Population Pharmacokinetic Analysis for Piperacillin/Tazobactam in Patients with End-Stage Kidney Disease Undergoing Intermittent Haemodialysis: Extension of a General-Purpose Model
A Population Pharmacokinetic Analysis for Piperacillin/Tazobactam in Patients with End-Stage Kidney Disease Undergoing Intermittent Haemodialysis: Extension of a General-Purpose Model Abstract Background and Objective End-stage kidney disease (ESKD) patients undergoing haemodialysis (HD) require a dosing regimen that b...
PMC3660081
core_pubmed_pmc
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study Abstract Background Metastatic colorectal cancer (mCRC) is commonly treated with 5-fluorouracil, folinic acid, and oxaliplatin or irinotecan. The multitargeted kinase inhib...
PMC10573114
core_pubmed_pmc
The Effect of Polymer Blends on the In Vitro Release/Degradation and Pharmacokinetics of Moxidectin-Loaded PLGA Microspheres
The Effect of Polymer Blends on the In Vitro Release/Degradation and Pharmacokinetics of Moxidectin-Loaded PLGA Microspheres Abstract To investigate the effect of polymer blends on the in vitro release/degradation and pharmacokinetics of moxidectin-loaded PLGA microspheres (MOX-MS), four formulations (F1, F2, F3 and F4...
PMC6466567
core_pubmed_pmc
A Review of the Clinical Pharmacokinetics of Polymyxin B
A Review of the Clinical Pharmacokinetics of Polymyxin B Abstract Abstract Polymyxin B remains an antibiotic of last resort because of its toxicities. Although newer therapies are becoming available, it is anticipated that resistance to these agents will continue to emerge, and understanding the safest and most efficac...
PMC8940815
core_pubmed_pmc
Inferring pulmonary exposure based on clinical PK data: accuracy and precision of model-based deconvolution methods
Inferring pulmonary exposure based on clinical PK data: accuracy and precision of model-based deconvolution methods Abstract Abstract Determining and understanding the target-site exposure in clinical studies remains challenging. This is especially true for oral drug inhalation for local treatment, where the target-sit...
PMC10196122
core_pubmed_pmc
Novel infusion strategy reduces severe adverse events caused by the anti-GD2 monoclonal antibody naxitamab
Novel infusion strategy reduces severe adverse events caused by the anti-GD2 monoclonal antibody naxitamab Abstract Introduction Anti-disialoganglioside 2 (anti-GD2) monoclonal antibodies (mAbs) are associated with Grade ≥3 (≥G3) adverse events (AEs) such as severe pain, hypotension, and bronchospasm. We developed a no...
PMC5651004
core_pubmed_pmc
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers Abstract Background: Calcitonin gene-related peptide (CGRP) is pivotal in the pathophysiology of migraine headaches and represents a promising target for migraine treatment...
PMC10878790
core_pubmed_pmc
Short peptides based on the conserved regions of MIEN1 protein exhibit anticancer activity by targeting the MIEN1 signaling pathway
Short peptides based on the conserved regions of MIEN1 protein exhibit anticancer activity by targeting the MIEN1 signaling pathway Abstract Abstract Migration and invasion enhancer 1 (MIEN1) overexpression characterizes several cancers and facilitates cancer cell migration and invasion. Leveraging conserved immunorece...
PMC12484572
core_pubmed_pmc
Integrative pharmacogenomics analysis predicts the platelet response in clopidogrel treated coronary artery disease (CAD) patients of South India
Integrative pharmacogenomics analysis predicts the platelet response in clopidogrel treated coronary artery disease (CAD) patients of South India Abstract Clopidogrel resistance/high on-treatment platelet reactivity (HTPR) has been associated with interindividual variability in the clopidogrel treatment response in dif...
PMC4876297
core_pubmed_pmc
Usage Pattern and Serum Level Measurement of Amikacin in the Internal Medicine Ward of the Largest Referral Hospital in the South of Iran: A Pharmacoepidemiological Study
Usage Pattern and Serum Level Measurement of Amikacin in the Internal Medicine Ward of the Largest Referral Hospital in the South of Iran: A Pharmacoepidemiological Study Abstract Abstract Background: The inappropriate use of aminoglycosides has harmful effects such as the development of resistant pathogens and the inc...
PMC8964367
core_pubmed_pmc
Berberine: A Review of its Pharmacokinetics Properties and Therapeutic Potentials in Diverse Vascular Diseases
Berberine: A Review of its Pharmacokinetics Properties and Therapeutic Potentials in Diverse Vascular Diseases Abstract Abstract Traditional Chinese medicine plays a significant role in the treatment of various diseases and has attracted increasing attention for clinical applications. Vascular diseases affecting vascul...
PMC12678863
core_pubmed_pmc
Association of SULT2A1 Locus With Abiraterone Clearance in the Alliance A031201: Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration‐Resistant Prostate Cancer
Association of SULT2A1 Locus With Abiraterone Clearance in the Alliance A031201: Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration‐Resistant Prostate Cancer Abstract ABSTRACT Enzalutamide and abiraterone are hormonal treatments that improve survival in meta...
PMC9835371
core_pubmed_pmc
Population Pharmacokinetic/Pharmacodynamic Modeling of the Effect of Abrocitinib on QT Intervals in Healthy Volunteers
Population Pharmacokinetic/Pharmacodynamic Modeling of the Effect of Abrocitinib on QT Intervals in Healthy Volunteers Abstract Abstract Abrocitinib is a selective Janus kinase 1 inhibitor for the treatment of moderate to severe atopic dermatitis (AD). To assess the relationship between abrocitinib plasma concentration...
PMC9059175
core_pubmed_pmc
Drug absorption in bariatric surgery patients: A narrative review
Drug absorption in bariatric surgery patients: A narrative review Abstract Abstract Background Despite the increase in the number of bariatric surgeries performed, little is known about the impact of the surgery on drug absorption. Unpredictability is assumed with drugs, given the anatomical changes after surgery. Obje...
PMC3413973
core_pubmed_pmc
Cutting Edge PBPK Models and Analyses: Providing the Basis for Future Modeling Efforts and Bridges to Emerging Toxicology Paradigms
Cutting Edge PBPK Models and Analyses: Providing the Basis for Future Modeling Efforts and Bridges to Emerging Toxicology Paradigms Abstract Abstract Physiologically based Pharmacokinetic (PBPK) models are used for predictions of internal or target dose from environmental and pharmacologic chemical exposures. Their use...
PMC3156980
core_pubmed_pmc
Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study
Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study Abstract Summary Background We report clinical safety and biochemical efficacy from a dose-ranging study of intravenously a...
PMC5427049
core_pubmed_pmc
Hyperlipidemia Alters the Pharmacokinetics of Posaconazole and Vincristine Upon Co-Administration in Rats
Hyperlipidemia Alters the Pharmacokinetics of Posaconazole and Vincristine Upon Co-Administration in Rats Abstract Objectives Co-administration of posaconazole (PSZ) and vincristine (VCR) in the treatment of patients with acute lymphoblastic leukemia increases the neurotoxicity of VCR. Our aim is to study the effect of...
PMC12155435
core_pubmed_pmc
Do We Know Enough About the Safety Profile of Silver Nanoparticles in Oncology? A Focus on Novel Methods and Approaches
Do We Know Enough About the Safety Profile of Silver Nanoparticles in Oncology? A Focus on Novel Methods and Approaches Abstract Abstract Silver nanoparticles (AgNPs) have emerged as promising agents in cancer diagnostics and/or therapy, demonstrating a lot of possible pharmacological actions. However, understanding th...
PMC3168467
core_pubmed_pmc
Targeted Drug Delivery by Gemtuzumab Ozogamicin: Mechanism-Based Mathematical Model for Treatment Strategy Improvement and Therapy Individualization
Targeted Drug Delivery by Gemtuzumab Ozogamicin: Mechanism-Based Mathematical Model for Treatment Strategy Improvement and Therapy Individualization Abstract Abstract Gemtuzumab ozogamicin (GO) is a chemotherapy-conjugated anti-CD33 monoclonal antibody effective in some patients with acute myeloid leukemia (AML). The o...
PMC4213730
core_pubmed_pmc
Validation of serum IGF-I as a biomarker to monitor the bioactivity of exogenous growth hormone agonists and antagonists in rabbits
Validation of serum IGF-I as a biomarker to monitor the bioactivity of exogenous growth hormone agonists and antagonists in rabbits Abstract The development of new growth hormone (GH) agonists and growth hormone antagonists (GHAs) requires animal models for pre-clinical testing. Ideally, the effects of treatment are mo...
PMC12555008
core_pubmed_pmc
A novel dual DYRK1A/B inhibitor for the treatment of type 1 diabetes
A novel dual DYRK1A/B inhibitor for the treatment of type 1 diabetes Abstract Background Type 1 diabetes (T1D) is an autoimmune disease that leads to the progressive destruction of pancreatic β cells, resulting in insulin deficiency and hyperglycemia. Current treatments focus on insulin replacement, but novel therapeut...
PMC10545697
core_pubmed_pmc
Novel computational and drug design strategies for inhibition of human papillomavirus-associated cervical cancer and DNA polymerase theta receptor by Apigenin derivatives
Novel computational and drug design strategies for inhibition of human papillomavirus-associated cervical cancer and DNA polymerase theta receptor by Apigenin derivatives Abstract Abstract The present study deals with the advanced in-silico analyses of several Apigenin derivatives to explore human papillomavirus-associ...
PMC11893401
core_pubmed_pmc
Pharmacokinetics and pharmacodynamics of insulin lispro 25 versus the original preparation (Humalog ® 25) in Chinese healthy male volunteers
Pharmacokinetics and pharmacodynamics of insulin lispro 25 versus the original preparation (Humalog ® 25) in Chinese healthy male volunteers Abstract Abstract Background: There are approximately 537 million adults with diabetes worldwide, and insulin still plays an important role in its treatment. However, the long-ter...
PMC5527233
core_pubmed_pmc
Pharmacokinetic Parameters and Over-Responsiveness of Iranian Population to Propranolol
Pharmacokinetic Parameters and Over-Responsiveness of Iranian Population to Propranolol Abstract Abstract Purpose: Propranolol is the most widely used treatment for cardiovascular diseases. Dosage range in our patients is usually less than the amount mentioned in references. The aim of the present study was to clarify ...
PMC11455736
core_pubmed_pmc
Pharmacokinetics, Mass Balance, and Biotransformation of [ 14 C]tinengotinib, A Novel Multi-target Kinase Inhibitor, in Healthy Subjects
Pharmacokinetics, Mass Balance, and Biotransformation of [ 14 C]tinengotinib, A Novel Multi-target Kinase Inhibitor, in Healthy Subjects Abstract Abstract Background and Objective Tinengotinib, a novel multi-target small molecule kinase inhibitor, is currently undergoing phase II clinical trial in the USA and China. Th...
PMC4985381
core_pubmed_pmc
Does Once-Daily Raltegravir Have Any Role in the Antiretroviral Treatment?
Does Once-Daily Raltegravir Have Any Role in the Antiretroviral Treatment? Abstract Abstract Administering raltegravir once daily would make adherence to antiretroviral treatment easier, especially if the concomitant drugs are also administered once daily. We report our experience on the use of raltegravir, both once- ...
PMC7759859
core_pubmed_pmc
Animal Safety, Toxicology, and Pharmacokinetic Studies According to the ICH S9 Guideline for a Novel Fusion Protein tTF-NGR Targeting Procoagulatory Activity into Tumor Vasculature: Are Results Predictive for Humans?
Animal Safety, Toxicology, and Pharmacokinetic Studies According to the ICH S9 Guideline for a Novel Fusion Protein tTF-NGR Targeting Procoagulatory Activity into Tumor Vasculature: Are Results Predictive for Humans? Abstract Simple Summary Non-clinical safety, toxicology, and pharmacokinetic studies according to ICH g...
PMC10900833
core_pubmed_pmc
Antibiotic dosing recommendations in critically ill patients receiving new innovative kidney replacement therapy
Antibiotic dosing recommendations in critically ill patients receiving new innovative kidney replacement therapy Abstract Background The Tablo Hemodialysis System is a new innovative kidney replacement therapy (KRT) providing a range of options for critically ill patients with acute kidney injury. The use of various ef...
PMC10286583
core_pubmed_pmc
Advances in the Therapeutic Use of Non-Ergot Dopamine Agonists in the Treatment of Motor and Non-Motor Symptoms of Parkinson’s Disease
Advances in the Therapeutic Use of Non-Ergot Dopamine Agonists in the Treatment of Motor and Non-Motor Symptoms of Parkinson’s Disease Abstract Abstract Dopamine (DA) agonists, as an excellent dopamine replacement therapy for patients with early and advanced Parkinson's disease (PD), play a vital role in controlling mo...
PMC7995992
core_pubmed_pmc
Peptidomimetics Therapeutics for Retinal Disease
Peptidomimetics Therapeutics for Retinal Disease Abstract Ocular disorders originating in the retina can result in a partial or total loss of vision, making drug delivery to the retina of vital importance. However, effectively delivering drugs to the retina remains a challenge for ophthalmologists due to various anatom...
PMC6785774
core_pubmed_pmc
Histological and toxicological evaluation, in rat, of a P-glycoprotein inducer and activator: 1-(propan-2-ylamino)-4-propoxy-9 H -thioxanthen-9-one (TX5)
Histological and toxicological evaluation, in rat, of a P-glycoprotein inducer and activator: 1-(propan-2-ylamino)-4-propoxy-9 H -thioxanthen-9-one (TX5) Abstract P-glycoprotein (P-gp) is an ATP-binding cassette transporter involved in the efflux of numerous compounds that influences the pharmacokinetics of xenobiotics...
PMC7094754
core_pubmed_pmc
Traditional Chinese Medicine of Angelicae Pubescentis Radix: A Review of Phytochemistry, Pharmacology and Pharmacokinetics
Traditional Chinese Medicine of Angelicae Pubescentis Radix: A Review of Phytochemistry, Pharmacology and Pharmacokinetics Abstract Angelicae Pubescentis Radix (APR) is a widely used antirheumatic Chinese medicinal herb known as “Duhuo” in China. It has the effects of dispelling wind and removing dampness, diffusing im...
PMC4446523
core_pubmed_pmc
Drug-Induced Renal Damage in Preterm Neonates: State of the Art and Methods for Early Detection
Drug-Induced Renal Damage in Preterm Neonates: State of the Art and Methods for Early Detection Abstract Only a small fraction of drugs widely used in neonatal intensive care units (NICU) are specifically authorized for this population. Even if unlicensed or off-label use is necessary, it is associated with increased a...